Perhaps you missed my last entry, but just so you know, Exelixis is flying high. I've been following this stock for the past three years, and I've seen extreme lows but some extreme highs like the past couple of months. I've lost a significant amount, but now it has more than made back my loss.
What caught my eye and drew me to this company? Look at the description...
Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.
Cancer treatments are the future with the aging baby boomers and other generations where cancer will still exist. I'll admit pharmaceuticals are risky since some other company may come up with a generic version. They are a roller coaster ride, so not for the weak hearted.
At one time, all the analysists said don't buy this stock or sell the stock if you have it. Look what they are saying now, here, here and here. Financial advisors might laugh at my layman's assessment. I'm just in shock and awe how this stock is currently flying high!
No comments:
Post a Comment